High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell, FV; Ssebambulidde, K; Grint, D; Te Brake, L; Musabire, A; Atherton, RR; Tugume, L; Muzoora, C; Lukande, R; Lamorde, M; +4 more... Aarnoutse, R; Meya, D; Boulware, DR; Elliott, AM; (2018) High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). Wellcome open research, 3. p. 83. ISSN 2398-502X DOI: https://doi.org/10.12688/wellcomeopenres.14691.1

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.12688/wellcomeopenres.14691.1

Abstract

Share

Download

Filename: Cresswell_etal_2018-high-dose-oral.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar